BRD2 and schizophrenia: The assumptions of this research are that (1) there are significant differences in NAT, CF and EA between individuals with schizophrenia when compared to an end-stage CKD group, and that (2) NAT represent a specific pathway to CF and EA in individuals with schizophrenia.